rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2006-2-4-47-52rpcardio-1052Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯFROM HOPE TRIAL TO ONTARGET TRIAL: THE «HOPE» TO REACH THE «TARGET» - TO IMPROVE PROGNOSIS IN HIGH RISK PATIENTSОТ ИССЛЕДОВАНИЯ «HOPE» К ИССЛЕДОВАНИЮ ONTARGET: «НАДЕЖДА» ДОСТИЧЬ «ЦЕЛЬ» - УЛУЧШИТЬ ПРОГНОЗ У БОЛЬНЫХ ВЫСОКОГО РИСКАЛопатинЮ. М.LopatinYu. M.Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центрРоссияVolgograd medical state university, Volgograd regional cardiology centreRussian Federation200624012016244752Copyright © Lopatin Y.M., 20162016Лопатин Ю.М.Lopatin Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1052

Results of HOPE trial are analyzed. It is noted, that treatment with angiotensine converting enzyme inhibitor (iACE) ramipril improves the prognosis in high risk cardio-vascular patients. The objectives and study design of ONTARGET/TRANSCEND trials are introduced. Perspectives of joint use of ACE inhibitor and antagonist of angiotensin II receptor are discussed.

Проанализированы результаты исследования HOPE. Отмечено, что назначение ингибитора ангиотензинпревращающего фермента (иАПФ) рамиприла больным высокого сердечно-сосудистого риска приводит к улучшению прогноза. Представлены цели и дизайн исследований ONTARGET/TRANSCEND. Обсуждаются перспективы совместного применения иАПФ и антагонистов рецепторов к ангиотензину II.

высокий сердечно-сосудистый рискрамиприлтелмисартанисследование НОРЕисследование ONTARGEThigh cardio-vascular riskramipriltelmisartanНОРЕ trialONTARGET trialReferencesThe Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-converting-enzyme inhibitor , ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153.The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-converting-enzyme inhibitor , ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153.Lonn E.M., Yusuf S., Dzavik V. et al. Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation. 2001; 103: 919-925.Lonn E.M., Yusuf S., Dzavik V. et al. Effects of Ramipril and Vitamin E on Atherosclerosis : The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation. 2001; 103: 919-925.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.Pitt B., O’Neill B., Feldman R. et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am.J.Cardiol. 2001; 87: 1058-1063.Pitt B., O’Neill B., Feldman R. et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am.J.Cardiol. 2001; 87: 1058-1063.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.The EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362: 782-788.The PEACE Trial Investigators. Angoitensin-converting enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351: 2058-2068.The PEACE Trial Investigators. Angoitensin-converting enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351: 2058-2068.Российские рекомендации по диагностике и лечению стабильной стенокардии. Приложение к журналу Кардиоваскулярная терапия и профилактика, 2004.Российские рекомендации по диагностике и лечению стабильной стенокардии. Приложение к журналу Кардиоваскулярная терапия и профилактика, 2004.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur . Heart J. 2006; 27: 1341-1381.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur . Heart J. 2006; 27: 1341-1381.Dagenais G.R., Pogue J., Fox K. Et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006; 368: 581-588.Dagenais G.R., Pogue J., Fox K. Et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006; 368: 581-588.The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluated telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with Cardiovascular Disease. Am. Heart J. 2004; 148: 52-61.The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluated telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with Cardiovascular Disease. Am. Heart J. 2004; 148: 52-61.Neutel J.M., Smith D.H.G. Dose response and anti-hypertensive efficacy of the AT1 receptor antagonist telmisartan in patients withmild to moderate hypertension. Adv. Ther . 1998; 15: 206-217.Neutel J.M., Smith D.H.G. Dose response and anti-hypertensive efficacy of the AT1 receptor antagonist telmisartan in patients withmild to moderate hypertension. Adv. Ther . 1998; 15: 206-217.WienenW., Entzeroth M., van Meel J.C.A. et al. A review on telmisartan: a novel, long-acting angiotensin II receptor antagonist. Cardiovasc. Drug Rev. 2000; 18: 127-156.WienenW., Entzeroth M., van Meel J.C.A. et al. A review on telmisartan: a novel, long-acting angiotensin II receptor antagonist. Cardiovasc. Drug Rev. 2000; 18: 127-156.McKelvie R.S., Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies fro left ventricular dysfunction (RESOLVD) pilot study : the RESOLVD Pilot Study Investigators.McKelvie R.S., Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies fro left ventricular dysfunction (RESOLVD) pilot study : the RESOLVD Pilot Study Investigators.Circulation. 1999; 100: 1056-1064.Circulation. 1999; 100: 1056-1064.McMurray J.J.V., Ostergrin J., Swedberg K. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-771.McMurray J.J.V., Ostergrin J., Swedberg K. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-771.

The authors declare that there are no conflicts of interest present.